CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced it will release its annual 2024 financial results after market close on March 4, 2025, followed by a conference call at 4:30 p.m. Eastern Time.
The specialty pharmaceutical company maintains a portfolio of FDA-approved brands including:
- Acetadote® for acetaminophen poisoning
- Caldolor® for pain and fever
- Kristalose® for constipation
- Sancuso® for chemotherapy-related nausea
- Vaprisol® for hyponatremia
- Vibativ® for bacterial infections
Additionally, Cumberland has Phase II clinical programs ongoing for its ifetroban candidate, targeting Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) ha annunciato che rilascerà i suoi risultati finanziari annuali 2024 dopo la chiusura del mercato il 4 marzo 2025, seguiti da una conferenza telefonica alle 16:30 ora orientale.
La società farmaceutica specializzata mantiene un portafoglio di marchi approvati dalla FDA tra cui:
- Acetadote® per avvelenamento da acetaminofene
- Caldolor® per dolore e febbre
- Kristalose® per costipazione
- Sancuso® per nausea correlata alla chemioterapia
- Vaprisol® per iponatriemia
- Vibativ® per infezioni batteriche
Inoltre, Cumberland ha programmi clinici di Fase II in corso per il suo candidato ifetroban, mirati alla Sclerosi Sistemica, alla cardiomiopatia associata alla Distrofia Muscolare di Duchenne e alla Fibrosi Polmonare Idiopatica.
Cumberland Pharmaceuticals (Nasdaq: CPIX) anunció que publicará sus resultados financieros anuales de 2024 después del cierre del mercado el 4 de marzo de 2025, seguido de una conferencia telefónica a las 4:30 p.m. hora del Este.
La compañía farmacéutica especializada mantiene un portafolio de marcas aprobadas por la FDA que incluye:
- Acetadote® para intoxicación por acetaminofén
- Caldolor® para el dolor y la fiebre
- Kristalose® para el estreñimiento
- Sancuso® para náuseas relacionadas con la quimioterapia
- Vaprisol® para hiponatremia
- Vibativ® para infecciones bacterianas
Además, Cumberland tiene programas clínicos de Fase II en curso para su candidato ifetroban, dirigido a la Esclerosis Sistémica, la cardiomiopatía asociada a la Distrofia Muscular de Duchenne y la Fibrosis Pulmonar Idiopática.
컴벌랜드 제약회사 (Nasdaq: CPIX)는 2025년 3월 4일 시장 폐장 후 2024 연간 재무 결과를 발표할 예정이며, 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜이 이어질 것이라고 발표했습니다.
이 전문 제약 회사는 다음과 같은 FDA 승인 브랜드 포트폴리오를 보유하고 있습니다:
- Acetadote® (아세트아미노펜 중독 치료제)
- Caldolor® (통증 및 발열 치료제)
- Kristalose® (변비 치료제)
- Sancuso® (항암 치료 관련 구역질 치료제)
- Vaprisol® (저나트륨혈증 치료제)
- Vibativ® (세균 감염 치료제)
추가로, 컴벌랜드는 2상 임상 프로그램을 진행 중이며, 이는 전신 경화증, 듀센느 근육병과 관련된 심근병증, 특발성 폐섬유증을 대상으로 하고 있습니다.
Cumberland Pharmaceuticals (Nasdaq: CPIX) a annoncé qu'elle publiera ses résultats financiers annuels 2024 après la fermeture du marché le 4 mars 2025, suivis d'une conférence téléphonique à 16h30, heure de l'Est.
La société pharmaceutique spécialisée dispose d'un portefeuille de marques approuvées par la FDA comprenant :
- Acetadote® pour l'intoxication au paracétamol
- Caldolor® pour la douleur et la fièvre
- Kristalose® pour la constipation
- Sancuso® pour les nausées liées à la chimiothérapie
- Vaprisol® pour l'hyponatrémie
- Vibativ® pour les infections bactériennes
De plus, Cumberland a des programmes cliniques de phase II en cours pour son candidat ifetroban, ciblant la sclérose systémique, la cardiomyopathie associée à la dystrophie musculaire de Duchenne et la fibrose pulmonaire idiopathique.
Cumberland Pharmaceuticals (Nasdaq: CPIX) gab bekannt, dass die Jahresfinanzergebnisse 2024 nach Börsenschluss am 4. März 2025 veröffentlicht werden, gefolgt von einer Telefonkonferenz um 16:30 Uhr Eastern Time.
Das Spezialpharmaunternehmen verfügt über ein Portfolio von von der FDA zugelassenen Marken, darunter:
- Acetadote® bei Paracetamolvergiftung
- Caldolor® bei Schmerzen und Fieber
- Kristalose® bei Verstopfung
- Sancuso® bei chemotherapiebedingter Übelkeit
- Vaprisol® bei Hyponatriämie
- Vibativ® bei bakteriellen Infektionen
Darüber hinaus hat Cumberland laufende Phase-II-Studien für seinen Kandidaten Ifetroban, der auf systemische Sklerose, kardiomyopathische Erkrankungen im Zusammenhang mit Duchenne-Muskeldystrophie und idiopathische Lungenfibrose abzielt.
- Diverse portfolio of 6 FDA-approved products
- Multiple Phase II clinical trials in progress
- Strategic focus on three distinct market segments
- None.
A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on
SOURCE: Cumberland Pharmaceuticals Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-annual-2024-financial-results-302384710.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release its 2024 annual financial results?
How many FDA-approved products does Cumberland Pharmaceuticals (CPIX) currently have in its portfolio?
What clinical trials is Cumberland Pharmaceuticals (CPIX) currently conducting with ifetroban?
What market segments does Cumberland Pharmaceuticals (CPIX) focus on?
